Beractant (Survanta)
Pulmonary surfactant
Beractant (Survanta)
Forms and strengths
Form: TabletStrength: 100 mg phospholipids/4 mL, 200 mg phospholipids/8 mL
References
Indication
- Beractant is used for prevention (prophylaxis) of respiratory distress syndrome (RDS) in premature infants at risk of developing RDS or with evidence of pulmonary immaturity.
- Beractant is used for treatment (rescue) of RDS confirmed by chest X-ray in premature infants who require mechanical ventilation.
- Its use has not been evaluated in infants weighing less than 600 g or more than 1750 g at birth, and there is no controlled experience combining it with experimental RDS therapies such as high-frequency ventilation or extracorporeal membrane oxygenation.
Pregnancy
- Beractant is administered directly to premature infants after birth, not to pregnant women, so pregnancy-related dosing information does not apply.
Breastfeeding
- Beractant is administered directly to premature infants after birth, not to breastfeeding mothers, so breastfeeding-related dosing information does not apply.
Geriatrics
- Beractant is used exclusively in premature infants and has no role in geriatric care.
Pediatrics
- Beractant's safety and efficacy have been established specifically in premature infants with or at risk of RDS.
- It should be administered only by, or under the supervision of, health professionals experienced in intubation, ventilator management, and general care of premature infants.
Dosage & Administration
- Each dose of beractant is 100 mg phospholipids per kg of birth weight (4 mL/kg), determined from the manufacturer's weight-based dosing chart; the infant is not reweighed for repeat doses.
- For prevention, give the first dose as soon as possible after an airway is established, preferably within 15 minutes of birth, in infants under 1250 g birth weight or with evidence of surfactant deficiency.
- For rescue treatment, give the first dose as soon as possible after RDS is confirmed by X-ray and the infant requires mechanical ventilation, preferably by 8 hours of age.
- Each dose is divided into 2 half-doses or 4 quarter-doses, instilled through a catheter into the endotracheal tube with the infant repositioned between fractional doses to ensure even lung distribution.
- Repeat doses may be given no sooner than 6 hours after the preceding dose if the infant remains intubated and still requires at least 30% inspired oxygen; radiographic confirmation of RDS is recommended before a repeat dose in infants who received a prevention dose.
- Up to 4 total doses may be given within the first 48 hours of life; no information is available on dosing more often than every 6 hours or beyond 48 hours of age.
- Warm the vial before use by standing at room temperature for at least 20 minutes or holding in the hand for at least 8 minutes; artificial warming methods should never be used.
- Suctioning the infant before dosing, at the clinician's discretion, may reduce the risk of mucous plugging; the infant should not be suctioned for 1 hour after dosing unless signs of airway obstruction appear.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Overdose with beractant has not been reported in humans.
- Based on animal data, overdose might cause acute airway obstruction.
- Treatment of overdose would be symptomatic and supportive.
Common side effects
- Transient bradycardia (slowed heart rate) commonly occurs during the dosing procedure.
- Transient oxygen desaturation commonly occurs during the dosing procedure.
- Pallor may occur during dosing.
- Vasoconstriction may occur during dosing.
- Transient low blood pressure (hypotension) may occur during dosing.
- Transient high blood pressure (hypertension) may occur during dosing.
- Low carbon dioxide levels (hypocarbia) may occur during dosing.
- High carbon dioxide levels (hypercarbia) may occur during dosing.
- Brief pauses in breathing (apnea) may occur during dosing.
- Rales or moist breath sounds can occur transiently after administration.
- Reflux of beractant back up through the endotracheal tube may occur during dosing.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Endotracheal tube blockage from mucous plugs can occur, particularly if pulmonary secretions were prominent before dosing; a blocked tube should be replaced immediately if suctioning does not clear it.
- Hyperoxia (excess blood oxygen) can develop rapidly after administration; failure to reduce ventilator support promptly can lead to lung overdistention and fatal pulmonary air leaks.
- Pulmonary hemorrhage has been reported.
- Increased risk of post-treatment sepsis has been observed, though it has not been associated with increased mortality.
- Intracranial hemorrhage has been reported, with a higher rate seen in beractant-treated infants than controls in some individual studies, though pooled data across all controlled studies showed no overall difference.
- Seizures have been reported.
- Intestinal perforation has been reported.
- Volvulus (twisting of the bowel) has been reported.
- Coagulopathy (a blood clotting disorder) has been reported.
- Renal failure has been reported.
- Aortic thrombosis has been reported.
- Seek immediate medical attention for signs of airway obstruction, a sudden drop in oxygen saturation, or a significant change in heart rate during or after dosing.
Use with caution
- Administer only in a highly supervised clinical setting with immediate availability of health professionals experienced in intubation, ventilator management, and care of premature infants.
- Monitor systemic oxygenation frequently and carefully after administration, since oxygenation and lung compliance can improve rapidly and hyperoxia can develop within minutes.
- Monitor arterial or transcutaneous oxygen and carbon dioxide levels before, during, and after administration.
- Suction infants with prominent pulmonary secretions before dosing to reduce the risk of endotracheal tube mucous plugging.
- If bradycardia or oxygen desaturation occurs during dosing, stop the dosing procedure and initiate appropriate measures before resuming.
- If reflux through the endotracheal tube occurs, stop administration and increase peak inspiratory pressure as needed until the tube clears.
- Use has not been evaluated in infants under 600 g or over 1750 g birth weight.
- No controlled experience exists using beractant together with experimental RDS therapies such as high-frequency ventilation or extracorporeal membrane oxygenation.
Contraindications
- There are no known contraindications to treatment with beractant.
Drug interactions
- No formal drug-drug interaction studies have been conducted with beractant.
Food interactions
- Not applicable; beractant is given by intratracheal instillation to premature infants, not taken by mouth.
Time of administration
- Beractant is given intratracheally in a hospital neonatal intensive care setting as soon as clinically indicated for prevention or rescue treatment of RDS, not on a schedule tied to meals or time of day.
Storage
- Store unopened vials refrigerated at 2°C to 8°C and protect from light.
- Vials warmed to room temperature but not used may be returned to the refrigerator once within 24 hours of warming; beractant should never be warmed and returned to the refrigerator more than once.
- Each single-use vial should be entered with a needle only once; discard any used vial with residual drug.
Patient take-away
- Beractant (Survanta) is a lung surfactant given directly into a premature baby's breathing tube in the neonatal intensive care unit to help prevent or treat respiratory distress syndrome.
- The medical team monitors the baby's heart rate, oxygen levels, and breathing closely during and after each dose, since brief changes can occur during the dosing procedure itself.
- Parents can ask their baby's care team about the number of doses planned and how their baby is responding to treatment.